ACR 2022
How Does Risk for CV Events Differ Between Tofacitinib and TNFi in RA?
Results of the ORAL Surveillance study showed a higher risk for major adverse CV events and venous thromboembolism with tofacitinib vs TNFis.
Your search for tofacitinib returned 13 results
ACG 2022
Insurance Companies Have Poor Adherence to Guidelines for UC, CD
The data were compared with the 2018 ACG and 2020 AGA guidelines for UC and the 2019 ACG and 2021 AGA guidelines for CD.
DDW 2022
Tofacitinib, Vedolizumab Effective for UC Post-Anti-TNF Agent Failure
Researchers compared the effectiveness of tofacitinib and vedolizumab among patients with UC who had experienced anti-TNF failure.
ACR 2019, News
Few Serious Infections in Offspring Exposed to Non-TNFi Biologics, Tofacitinib
Researchers compared the risk for serious infections in offspring of mothers with chronic inflammatory diseases who received non-TNFi biologics or tofacitinib during pregnancy vs offspring who were unexposed, but exposed to TNFi in utero.
ACR/ARHP 2018 Annual Meeting
CVD Risk Reduced in Rheumatoid Arthritis Treated With Methotrexate and bDMARDs
A reduction in risk for cardiovascular disease has been reported among patients with rheumatoid arthritis who are receiving concomitant therapy with methotrexate and biologic disease-modifying antirheumatic drugs.
ACR/ARHP 2018 Annual Meeting
Venus Thromboembolism Risk Assessed With Tofacitinib, TNF Inhibitors
Although the incidence rate of venous thromboembolism was numerically higher in patients treated with tofacitinib vs TNF inhibitors, the risk was not statistically significant.
ACR/ARHP 2018 Annual Meeting
Abatacept May Reduce Diabetes Risk in Rheumatoid Arthritis
The researchers concluded their findings indicate that for patients with RA, abatacept reduced the risk for diabetes and "potentially improved insulin sensitivity and glycemic profile."
ACR/ARHP 2018 Annual Meeting
RA Remission Compared for Tofacitinib Alone vs. Steroid Plus Tofacitinib Tx
The results support combination therapy with intra-articular steroid injections and tofacitinib to achieve clinical and radiographic remission in patients with early rapid radiographic progression RA.
ACR/ARHP 2018 Annual Meeting
Clinical Efficacy of Tofacitinib Once-Daily vs Twice-Daily Examined in RA
Tofacitinib extended release has comparable clinical efficacy to tofacitinib administered twice daily.
ACR/ARHP 2018 Annual Meeting
Ustekinumab and Secukinumab Safe, Efficacious for Psoriatic Arthritis
Among a new line of biological and targeted synthetic DMARD, ustekinumab and secukinumab have shown favorable safety and efficacy profiles for psoriasis and arthritis, respectively in patients with psoriatic arthritis.
